Peripheral blood CD34 þ cell samples from eight children with advanced neuroblastoma and from 10 healthy adult donors were seeded at 5 Â 10 4 cells/ml in stroma-free, serum-free medium with FL, SCF, MGDF (100 ng/ml each), G-CSF, IL6 (10 ng/ml each) and IL3 (5 ng/ml), and incubated for 10 days. The levels of expansion of PBCD34 þ cells observed in neuroblastoma patients, with up to 214-fold expansion for total nucleated cells, 39-fold for CD34 þ cells, 79-fold for CFU-GM and ninefold for LTC-IC were identical to those obtained with PBCD34 þ cells of healthy donors (PX0.5). All samples from patients with neuroblastoma and five donor's PBCD34 þ cell samples contaminated with IMR-32 neuroblasts, were screened for the number of tyrosine hydroxylase (TH) mRNA transcript using LightCycler software. In all samples, progressive 1.9-4.4 log decreases in the number of TH transcripts were observed between days 0 and 10 of expansion. Our results show that in extensively pretreated children with neuroblastoma, the culture conditions that were effective for BM and CB cell expansion can generate an expansion of PBCD34 þ cells and provide a purge of tumour cells.
High-dose chemotherapy with autologous haemopoietic stem cell support improve both event-free and overall survival of neuroblastoma patients. 1, 2 However, the use of autologous peripheral blood stem cell (PBSC) or bone marrow (BM) in these patients is limited by two main considerations. First, contamination of a significant number of these grafts with clonogenic tumour cells 3, 4 that may contribute to relapse as was clearly demonstrated by gene-marking studies. 5, 6 Second, harvest difficulties in these extensively pretreated and small (low body weight) patients. One can postulate that the transplantation of ex vivo expanded haemopoietic progenitor cells may both reduce the risk of infusion of tumour cells (smaller starting tumour inoculum and purging during expansion) and reduce the scale of harvesting (multiplication of small initial aliquots of BM or PBSC).
Over the past decade, the possibility of increasing the number of haemopoietic progenitor cells through ex vivo culture has been demonstrated in adult patients and the clinical use of such ex vivo expanded cells has been reported in breast cancer and myeloma. 7, 8, 9 However, to our knowledge there has been no report on the feasibility of ex vivo expansion in paediatric patients with cancer.
Therefore, the aim of this study was to evaluate whether, in extensively pretreated children with neuroblastoma, the culture conditions that are effective for BM and CB cell expansion 10, 11 would generate an expansion of PBSCs and provide a purge of tumour cells.
Materials and methods

Cell samples
Cryopreserved PBCD34 þ cell samples from eight patients with neuroblastoma and from 10 healthy adult PBSC donors were obtained from a local blood bank. All donors gave their informed consent. All patients with stage IV neuroblastoma and BM involvement at diagnosis (cytology slides) had received four to six courses of sequential chemotherapy prior to PBSC mobilisation (Table 1) . PBSCs from both patients and donors were mobilised with G-CSF alone at 10 mg/kg/day (filgrastim, Amgen, Thousand Oaks, CA, USA) and collected with Cobe Spectra separator (Cobe, Lakewood, CO, USA). CD34 þ cells were selected using Ceprate (CellPro, Bothell, WA, USA) or Miltenyi (Miltenyi, Biotec, Bergisch, Germany) device (five and 13 experiments, respectively) and cryopreserved at -1961C as described previously.
12 CD34 þ cell samples were stored for a median of 7 months before thawing and seeding for ex vivo expansion. Median purity of CD34 þ cells at seeding was 95%.
Ex vivo expansion of PBCD34 þ cells PBCD34 þ cells were seeded in 175 cm 2 flasks (Falcon, Beckton Dickinson) at 5 Â 10 4 cells/ml in 4 ml of stromafree, serum-free medium (Iscove's medium supplemented with folic acid, l-glutamine, heparin, hydrocortisone hemisuccinate, myoinositol, monothioglycerol, bovine serum albumin, transferrin, bovine insulin, soybean lecithin and cholesterol) 13 with FL, SCF, MGDF (100 ng/ml each), G-CSF, IL6 (10 ng/ml each) and IL3 (5 ng/ml). Cultures were incubated at 371C in a humidified atmosphere with 5% CO 2 . A measure of 16 ml of fresh medium containing cytokines was added to each flask on day 6. Cells were collected on day 10, washed and analysed. Cell expansion was expressed as the fold increase, which was calculated by dividing the output absolute number of cells and progenitors after 10 days of expansion by the respective input number on day 0.
Phenotypic analysis and clonogenic assays
Total nucleated cell (TNC) counts, trypan blue viability assays and in vitro assays for myeloid, erythroid and megakaryocytic progenitor cells 14 as well as limiting dilution LTC-IC assays and flow cytometry analysis were performed both before and after expansion as described previously.
10,11
Minimal residual disease quantification All samples from patients with neuroblastoma and five donor's CD34 þ cell samples contaminated with 0.1 and 0.01% of IMR-32 neuroblasts were screened for the presence of tyrosine hydroxylase (TH) mRNA transcript (a neuroblastoma cell-specific marker) at days 0, 7, and 10 of expansion. The number of transcripts in samples was calculated with the LightCycler software, using the calibration data obtained with serial dilutions of purified PCR products containing known numbers of cDNA molecules of each gene. The results of real-time PCR for TH mRNA are given as the number of TH transcripts detected per 10 6 GAPDH transcripts. 3 
Results
Cell expansion
In the 10 healthy PBSC donors, the median levels of expansion obtained were: TNC 129-fold, CD34 þ cell 15-fold, CFU-GM 55-fold and LTC-IC nine-fold (Table 2) . These results are similar to those already reported concerning expansion under the same culture conditions of donor BMCD34 þ (TNC 293-fold, CD34 þ cell 20-fold, CFU-GM 67-fold and LTC-IC 27-fold) and CBCD34 þ (TNC 1262-fold, CD34 þ cell 42-fold, CFU-GM 120-fold and LTC-IC 10-fold) cells. 10, 11 In the neuroblastoma patients, the median TNC harvest after ex vivo expansion was 28.3 Â 10 6 (range 20.8-42.7) cells with a median 142-fold (range 110-214) expansion. The median number of CD34 þ cells harvested from the expansion cultures was 2.9 Â 10 6 (range 0.6-7.6) with a median 17-fold (range 3-39) expansion. Levels of expansion were up to 61-fold for AC133 þ cells (median 29), 28-fold for CD34 þ /AC133 þ /CXCR4 þ cells (median 20), 79-fold for CFU-GM (median 61) and nine-fold for LTC-IC (median 4). As far as the megakaryocyte lineage was concerned up to 746-fold expansion of CD34 þ /CD41 þ / CD61 þ cells (median 497) and 27-fold of CFU-MK (median 21) were noted. These levels of expansion are identical to those obtained in healthy donors as shown in Table 2 .
Minimal residual disease
All donor samples were negative for TH transcripts preand postexpansion. Donor samples subsequently contaminated with IMR-32 neuroblasts showed progressive decrease in the number of TH transcripts. Tumour cell depletion between days 0 and 10 of expansion was estimated to be 3.2 logs for 0.01% and 4.3 logs for 0.1% initial neuroblast inoculum, respectively. Six of eight neuroblastoma CD34 þ cell samples were positive for TH Table 1) . Kinetics of the decrease of TH transcript in neuroblastoma patient samples (a median of 998 copies on day 7 and 0 copies on day 10) were similar to those observed in contaminated donor samples (data not shown). Median tumour cell depletion in neuroblastoma patient samples was 3.1 logs (range 1.9-4.4).
Discussion
We have previously demonstrated the purging efficiency of CD34 þ cell immunoselection and the feasibility of PBCD34 þ cell transplantation in children with neuroblastoma. 3, 12, 15 In this study, we explore the possibility of both increasing the number of progenitor cells and reducing the number of tumour cells in the PBCD34 þ cell grafts of these patients.
First, we have shown that the combination of cytokines SCF, FL, MGDF, G-CSF, IL3, IL6, chosen on the basis of previous studies on BMCD34 þ and CBCD34 þ cell expansion can efficiently support the expansion of G-CSF mobilised PBCD34 þ cells from patients with neuroblastoma. The various combination of growth factors were tested to determine the most efficient ex vivo conditions for haematopoietic stem cell expansion. 10, 11 It was shown that PBCD34 þ cells, as BMCD34 þ cells, require interactions of six cytokines for optimal expansion.
It was found that these culture conditions allow expansion of up to 214-fold TNCs, 39-fold CD34 þ cells and 79-fold CFU-GM. These levels of expansion in these neuroblastoma patients are identical to those obtained with the PBSCs of the healthy donors under the same culture conditions (PX0.5). These results are also broadly comparable to those previously reported concerning the expansion of PBCD34 þ cells from patients with breast cancer: 15-fold for TNCs, two-fold for CD34 þ cells or myeloma: 34-fold for TNCs, three-fold for CD34 þ cells, 14-fold for CFU-GM. 8, 9 Considering the median level of expansion, we can speculate that, after a 10-day culture in a clinical setting, a graft product approximately equivalent to the minimal progenitor cell harvest for optimal engraftment (5 Â 10 6 CD34 þ cell/kg) would be obtained with only 1/10 of the quantity of PBSCs normally collected.
As our patients with neuroblastoma transplanted with PBCD34 þ have delayed platelet recovery, 12, 15 we were interested in quantifying the impact of our culture condition on the megakaryocyte lineage. Megakaryocyte progenitor generation was observed with up to 497-fold increase of CD34 þ /CD41 þ /CD61 þ cells and up to 27-fold increase of CFU-MK. This finding consolidates the hypothesis that expanded cells may affect not only neutrophil engraftment but also platelet recovery. Second, we have demonstrated that neuroblastoma cell elimination during expansion occurs when PBCD34 þ cells, contaminated with neuroblasts, are expanded in our culture system. Therefore we have confirmed that, as in adults with breast cancer, 7 ex vivo expansion is an effective strategy for purging PBSC autologous grafts in children with neuroblastoma. The overall PBSC graft purging level can be estimated as the sum of the following: (1) the smaller starting inoculum (1/10 of usually used graft equals 1 log reduction), (2) immunoselection purging (2-3 log reduction) and (3) purging during expansion (2-4 log reduction). Therefore a total of 5-8 log tumour cell reduction for an expanded PBCD34 þ cell graft vs a typical unselected and unexpanded autologous PBSC graft would be expected.
In conclusion, our results show that in extensively pretreated children with neuroblastoma, a significant ex vivo expansion of PBCD34 þ cell occurs together with tumour cell purge after a 10-day culture in a stroma-free, serum-free medium with FL, SCF, MGDF, G-CSF, IL3, IL6. On the basis of these findings, the initial PBPC harvesting could be reduced. These data constitute a rational for the potential clinical use of ex vivo expanded PBCD34 þ cells. In addition, this expansion system may be useful in those who mobilise stem cells poorly or for situations in which a large number of progenitor cells must be obtained to ensure haematopoietic support for multiple cycles of high-dose chemotherapy. 
